These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23899641)

  • 1. Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center.
    Silver H; Bilker WB
    J Clin Psychopharmacol; 2013 Oct; 33(5):710-1. PubMed ID: 23899641
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
    Takahashi H; Sugita T; Higuchi H; Shimizu T
    Hum Psychopharmacol; 2002 Mar; 17(2):95-8. PubMed ID: 12404698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.
    Chaichan W
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):364-8. PubMed ID: 15298648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms.
    Silver H; Aharon N; Kaplan A
    Schizophr Bull; 2003; 29(3):541-6. PubMed ID: 14609247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients.
    Silver H; Susser E; Danovich L; Bilker W; Youdim M; Goldin V; Weinreb O
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):573-84. PubMed ID: 21208484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative symptoms of schizophrenia are improved by paroxetine added to neuroleptics: a pilot study.
    Jockers-Scherübl M; Godemann F; Pietzcker A
    J Clin Psychiatry; 2001 Jul; 62(7):573. PubMed ID: 11488373
    [No Abstract]   [Full Text] [Related]  

  • 7.
    Boyle K; Cornett S; Fijtman A; Hunt-Harrison T
    J Child Adolesc Psychopharmacol; 2021 Sep; 31(7):514-515. PubMed ID: 34166111
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms.
    Arango C; Kirkpatrick B; Buchanan RW
    J Nerv Ment Dis; 2000 Jan; 188(1):50-3. PubMed ID: 10665462
    [No Abstract]   [Full Text] [Related]  

  • 9. No effects of antidepressants on negative symptoms in schizophrenia.
    Hinkelmann K; Yassouridis A; Kellner M; Jahn H; Wiedemann K; Raedler TJ
    J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
    Lu ML; Lane HY; Chen KP; Jann MW; Su MH; Chang WH
    J Clin Psychiatry; 2000 Aug; 61(8):594-9. PubMed ID: 10982203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
    Silver H
    Int Clin Psychopharmacol; 2003 Nov; 18(6):305-13. PubMed ID: 14571150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.
    Lu ML; Chen TT; Kuo PH; Hsu CC; Chen CH
    Schizophr Res; 2018 Mar; 193():126-133. PubMed ID: 28688742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenia and obsessive-compulsive disorder.
    Devulapalli K; Nasrallah HA
    Am J Psychiatry; 2010 Nov; 167(11):1407-8. PubMed ID: 21041254
    [No Abstract]   [Full Text] [Related]  

  • 14. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.
    Szegedi A; Anghelescu I; Wiesner J; Schlegel S; Weigmann H; Härtter S; Hiemke C; Wetzel H
    Pharmacopsychiatry; 1999 Jul; 32(4):148-53. PubMed ID: 10505485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine for psychosis in Alzheimer's disease.
    Levkovitz Y; Bloch Y; Kaplan D; Diskin A; Abramovitchi I
    J Nerv Ment Dis; 2001 Feb; 189(2):126-9. PubMed ID: 11225688
    [No Abstract]   [Full Text] [Related]  

  • 16. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.
    Silver H; Shmugliakov N
    J Clin Psychopharmacol; 1998 Jun; 18(3):208-11. PubMed ID: 9617979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
    Silver H
    Expert Opin Pharmacother; 2004 Oct; 5(10):2053-8. PubMed ID: 15461540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.
    Yasui-Furukori N; Kondo T; Mihara K; Inoue Y; Kaneko S
    Psychopharmacology (Berl); 2004 Jan; 171(2):223-7. PubMed ID: 12955290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine.
    Preskorn SH
    J Psychiatr Pract; 2005 May; 11(3):192-6. PubMed ID: 15920392
    [No Abstract]   [Full Text] [Related]  

  • 20. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
    Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ
    Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.